S.1734 - Generating Antibiotic Incentives Now Act of 2011

A bill to provide incentives for the development of qualified infectious disease products. view all titles (2)

Close

All Bill Titles

  • Official: A bill to provide incentives for the development of qualified infectious disease products. as introduced.
  • Short: Generating Antibiotic Incentives Now Act of 2011 as introduced.

This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.

Bill's Views

  • Today: 1
  • Past Seven Days: 6
  • All-Time: 1,435
 
Introduced
 
Senate
Passes
 
House
Passes
 
President
Signs
 

 
10/18/11
 
 
 
 
 
 
 

Official Bill Text Comment on about 13 Pages

Sponsor

Senator

Richard Blumenthal

D-CT

View Co-Sponsors (14)

Official Summary

10/19/2011--Introduced.Generating Antibiotic Incentives Now Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for a new prescription drug by five years for a drug that the Secretary of Health and Human Services (HHS) determines to be a qualified
Close

Official Summary

10/19/2011--Introduced.Generating Antibiotic Incentives Now Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to extend the exclusivity period for a new prescription drug by five years for a drug that the Secretary of Health and Human Services (HHS) determines to be a qualified infectious disease product. Defines "qualified infectious disease product" to mean an antibiotic drug for treating, detecting, preventing, or identifying a qualifying pathogen (certain pathogens that are resistant to antibiotics). Excludes drugs that are:
(1) a supplement to a new drug application for which an extension is in effect or has expired; or
(2) a subsequent application for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or a modification to the structure of the product that does not result in a change in safety or effectiveness. Extends such period of exclusivity an additional six months for a sponsor or manufacturer of a qualified infectious disease product that identifies a companion diagnostic test. Requires the Secretary to give priority review to any drug determined to be a qualified infectious disease product. Includes qualified infectious disease products as fast track products for which the Secretary shall facilitate development and expedite review. Directs the Comptroller General to study the need for incentives to encourage the research, development, and marketing of qualified infectious disease biological products. Requires the Secretary to:
(1) review Food and Drug Administration (FDA) guidelines for clinical trials of antibiotic drugs; and
(2) revise such guidelines, as appropriate, to reflect developments in scientific and medical information and technology and to ensure clarity regarding the procedures and requirements for approval of an antibiotic drug.

...Read the Rest


Latest Letters to Congress

See All Letters (3)
 


Vote on This Bill

100% Users Support Bill

2 in favor / 0 opposed
 

Send Your Senator a Letter

about this bill Support Oppose Tracking
Track with MyOC
Save to Notebook Make A Bill Widget

OC Blog Articles Related To This Bill

Recent OC Blog Articles

OpenCongress is a free and open-source project of the Participatory Politics Foundation, a 501(c)3 non-profit organization with a mission to increase civic engagement. The non-profit Sunlight Foundation is the Founding and Primary Supporter of OpenCongress.